The Business Research Company's Viral Vector Production (Research-Use) Market to Reach USD $3.1 Billion by 2029 at 15% CAGR LONDON, GREATER LONDON, UNITED KINGDOM, October 15, 2025 / EINPresswire.com ...

Receiving a platform technology designation from the FDA is a tremendous milestone for our development team and Krystal, both as recognition of the reproducibility and scalability of our HSV-1 gene ...

The viral vector gene therapy market size is calculated at USD 14.62 billion in 2025 and is expected to reach around USD ...

A major challenge in AAV gene therapy has been developing scalable, cost-efficient processes to reliably produce high-quality vectors.

Emerging opportunities in the viral vector manufacturing market include personalized medicine growth, expanded clinical trials, and regional manufacturing partnerships. Advances in bioprocessing and ...

Thermo Fisher will equip Dr. Park CDMO’s new facility with advanced bioreactors to scale viral vector manufacturing.

Gene therapy offers the possibility of addressing cancer at its molecular roots by targeting disease-causing genes rather than relying solely on surgery, chemotherapy, or radiotherapy. Among RNA-based ...

OXB acquires Resilience’s site in North Carolina, an FDA-approved, commercial-scale viral vector manufacturing facility In line with OXB’s ...

IB [email protected] ReiThera to Showcase Innovative Viral Vector Platforms at ESGCT 2025Rome, Italy – September 30 2025 – ReiThera Srl, the Italian leading Contract Development ...

OXB has signed and closed an asset purchase transaction to acquire a custom-built cell and gene therapy viral vector manufacturing facility in ...